1. Home
  2. RPTX vs IVA Comparison

RPTX vs IVA Comparison

Compare RPTX & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Repare Therapeutics Inc.

RPTX

Repare Therapeutics Inc.

HOLD

Current Price

$2.16

Market Cap

92.4M

Sector

Health Care

ML Signal

HOLD

Logo Inventiva S.A. American Depository Shares

IVA

Inventiva S.A. American Depository Shares

HOLD

Current Price

$4.20

Market Cap

769.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RPTX
IVA
Founded
2016
2011
Country
Canada
France
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
92.4M
769.0M
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
RPTX
IVA
Price
$2.16
$4.20
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
7
Target Price
$3.00
$17.14
AVG Volume (30 Days)
751.5K
212.9K
Earning Date
11-14-2025
09-29-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$11,870,000.00
$19,929,536.00
Revenue This Year
N/A
N/A
Revenue Next Year
$9.55
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.89
$2.11
52 Week High
$2.30
$7.98

Technical Indicators

Market Signals
Indicator
RPTX
IVA
Relative Strength Index (RSI) 55.66 45.89
Support Level $2.11 $4.32
Resistance Level $2.27 $4.71
Average True Range (ATR) 0.06 0.23
MACD -0.01 0.02
Stochastic Oscillator 28.13 30.14

Price Performance

Historical Comparison
RPTX
IVA

About RPTX Repare Therapeutics Inc.

Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.

About IVA Inventiva S.A. American Depository Shares

Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.

Share on Social Networks: